At BioJapan 2025, Prof. Yoshiaki Tsukamoto, Executive Director of the Japan Bioindustry Association (JBA), shared with GeneOnline how Japan’s 2:1 fund-matching program and dual-use biomanufacturing initiatives are reshaping its innovation landscape. From AGC Group’s new Yokohama biomanufacturing hub to FUJIFILM Corporation’s large-scale CDMO expansion in Toyama, Japan’s biotech is shifting from pure research to scalable production. The government’s incentive stack is transforming lab innovations into market-ready ventures — turning science into business. Global interest is rising fast. Strategic partnerships with the UK, France, Italy, Australia, Taiwan, and Korea signal Japan’s growing presence as a biotech and investment hub in the Asia-Pacific. Yet, as Prof. Tsukamoto highlights, Japan’s challenge remains in bridging strong science with commercialization: “We want international capital to look at Japan’s early-stage startups — BioJapan is the best gateway.”
Read the full interview articles here:
EN – https://bit.ly/4oMuzYu
CH – https://bit.ly/3Yg1b1L
